Diffuse large B-cell lymphoma stage II is a fast-growing cancer that affects the body’s immune system, but with today’s treatment approaches, many patients can achieve lasting remission and return to their normal lives.

Understanding Treatment Goals in Stage II Disease

When someone receives a diagnosis of stage II diffuse large B-cell lymphoma, the primary aim of treatment is to achieve complete remission and, ideally, a cure. Stage II means that the lymphoma affects more than one group of lymph nodes, but all of them are located on the same side of the diaphragm, which is the sheet of muscle that separates the chest from the stomach area. This is still considered an early or localized stage of the disease, which means the cancer has not spread widely throughout the body.^[5]

Treatment decisions depend on several factors beyond just the stage. Doctors consider the patient’s age, overall health, specific symptoms, whether the lymphoma is causing certain warning signs known as B symptoms, and how large any swollen lymph nodes are. The presence of what doctors call bulky disease—meaning very large masses—can also influence which treatment approach is best. Because this type of lymphoma grows quickly, symptoms can appear or worsen in just a few weeks, which is why treatment usually begins soon after diagnosis.^[3]

Modern medicine has made remarkable progress in treating this condition. While diffuse large B-cell lymphoma is aggressive, it is often curable, especially when caught and treated early. Medical researchers continue to study new therapies through clinical trials, seeking ways to improve outcomes for patients whose disease proves harder to treat or comes back after initial therapy.^[1]

Standard Treatment Approaches

The foundation of standard treatment for stage II diffuse large B-cell lymphoma is a combination of chemotherapy drugs given together with a targeted antibody medicine. This approach is called chemoimmunotherapy, meaning it combines traditional cancer-killing drugs with a biological therapy that helps the immune system fight the cancer.^[3]

The most widely used regimen is known as R-CHOP. This acronym stands for rituximab combined with cyclophosphamide, doxorubicin (also called hydroxydaunorubicin), vincristine (brand name Oncovin), and prednisone. Each of these drugs works in a different way to attack cancer cells. Rituximab is a monoclonal antibody, which means it is a laboratory-made protein that attaches to a specific marker called CD20 on the surface of the abnormal B cells, helping the body’s immune system destroy them. The chemotherapy drugs work by interfering with the cancer cells’ ability to grow and divide.^[9][12]

R-CHOP is typically given in cycles, with each cycle lasting either 14 or 21 days. The 21-day cycle is most common. Patients usually receive an average of six cycles, though the exact number can vary based on individual circumstances and how the lymphoma responds. For patients with stage II disease, some doctors recommend three or four cycles of R-CHOP followed by radiation therapy to the affected area.^[9][11]

In certain situations, doctors may modify the standard regimen. For example, some patients receive R-EPOCH, where the drugs etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin are given along with rituximab but delivered as a continuous infusion over four days rather than as a single injection. Another variation is R-CHOEP, which adds the drug etoposide to the standard R-CHOP combination. Studies have shown that these intensified chemotherapy approaches can be superior to R-CHOP in certain situations.^[9][11]

Another treatment option approved for use in diffuse large B-cell lymphoma is polatuzumab vedotin-piiq, known by the brand name Polivy. This drug can be given in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone, creating a regimen called pola-R-CHP. This substitutes polatuzumab for vincristine in the traditional R-CHOP combination.^[9]

Radiation therapy may be added after chemotherapy, particularly for patients with limited stage disease like stage II. Radiation uses high-energy beams to destroy cancer cells in specific areas of the body. When used after chemotherapy in early-stage disease, it can help ensure that any remaining cancer cells in the treated lymph node areas are eliminated.^[11][12]

Managing Side Effects of Standard Treatment

The drugs used in R-CHOP and similar regimens can cause various side effects, though not every patient experiences all of them. Common side effects include fatigue, nausea, hair loss, increased risk of infection due to lowered white blood cell counts, and numbness or tingling in the hands and feet from vincristine. Doxorubicin can affect the heart, so doctors monitor heart function during treatment. Prednisone, a steroid, can cause increased appetite, mood changes, and elevated blood sugar levels.^[8]

Medical teams provide supportive care to help manage these side effects. This might include medications to prevent nausea, antibiotics or other drugs to prevent infections, and growth factors that stimulate the bone marrow to produce more white blood cells. Patients receiving treatment should report any new or worsening symptoms to their healthcare team promptly.^[12]

Emerging Therapies in Clinical Trials

While R-CHOP and similar regimens cure many patients with stage II diffuse large B-cell lymphoma, medical researchers continue to search for better treatments through clinical trials. These studies test new drugs, new combinations of existing drugs, or entirely new approaches to fighting the disease.

Targeted Therapies Based on Lymphoma Subtypes

Scientists have discovered that diffuse large B-cell lymphoma is not just one disease but includes several distinct subtypes with different genetic characteristics. Using a technique called gene expression profiling, researchers have identified two main forms: activated B cell-like (ABC) and germinal center B-cell-like (GCB) types. The ABC subtype tends to have a worse prognosis after R-CHOP therapy compared to the GCB subtype.^[11]

This discovery has led to research into customized treatments based on a patient’s specific subtype. For example, a drug called ibrutinib (brand name Imbruvica), which is already approved for other types of lymphoma, has been studied in clinical trials for diffuse large B-cell lymphoma. In a Phase II trial of patients whose disease had returned or did not respond to initial treatment, the ABC subtype showed much better response to ibrutinib than the GCB subtype. This finding is particularly important because the ABC subtype is more likely to respond poorly to standard R-CHOP treatment. Based on these results, an international Phase III trial was launched to compare standard chemotherapy with or without ibrutinib specifically in patients with the ABC subtype.^[9]

Ibrutinib is a type of targeted therapy that works by blocking a specific enzyme involved in the growth and survival of cancer cells. Unlike traditional chemotherapy, which affects all rapidly dividing cells, targeted therapies are designed to attack cancer cells more precisely while causing less damage to normal cells.

Understanding Clinical Trial Phases

Clinical trials proceed through different phases, each with a specific purpose. Phase I trials test whether a new treatment is safe and help determine the best dose. These studies typically involve a small number of patients. Phase II trials evaluate whether the treatment works against the cancer and continues to monitor safety. Phase III trials compare the new treatment to the current standard treatment to see if it is better, equally effective, or has fewer side effects. These trials involve larger numbers of patients and provide the evidence needed for regulatory approval of new treatments.

Novel Drug Combinations and Mechanisms

Beyond ibrutinib, researchers are investigating many other promising molecules and treatment approaches in clinical trials. Some studies focus on combining new drugs with standard chemotherapy to improve cure rates in newly diagnosed patients. Others test completely new classes of drugs that work through different mechanisms than traditional chemotherapy.

One area of active research involves drugs that target specific molecular pathways that cancer cells use to grow and survive. Next-generation sequencing, a powerful technology that can read the complete genetic code of cancer cells, has identified unique genetic mutations and abnormalities in different patients’ lymphomas. This genetic complexity provides researchers with rational therapeutic targets—specific molecules or pathways they can aim to block with new drugs.^[11]

Some clinical trials are investigating whether intensified chemotherapy regimens can improve outcomes. Studies have reported that dose-adjusted EPOCH-R was superior to R-CHOP in certain situations. These findings have led to ongoing trials to determine which patients benefit most from more intensive treatment approaches.^[11]

Advanced Treatment Options for Relapsed Disease

For patients whose lymphoma returns after initial treatment or does not respond adequately, clinical trials are exploring advanced options. One promising approach is CAR T-cell therapy, which involves collecting a patient’s own immune cells, genetically modifying them in a laboratory to recognize and attack lymphoma cells, and then infusing them back into the patient. This therapy has shown remarkable results in some patients with relapsed or refractory disease.^[12]

High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation is another option that has become established for patients whose disease comes back. In this approach, doctors collect the patient’s own blood-forming stem cells before giving very high doses of chemotherapy to destroy the lymphoma. The stem cells are then returned to the patient to rebuild the bone marrow and immune system.^[12]

Biomarkers and Personalized Treatment

Researchers are also studying various biomarkers—measurable indicators in blood or tissue—that can help predict how a patient’s lymphoma will respond to treatment. For example, some studies examine whether the presence of certain proteins on the surface of lymphoma cells, such as CD5, affects prognosis. Understanding these biomarkers will be crucial for developing individualized treatment approaches in the future, allowing doctors to tailor therapy to each patient’s specific type of lymphoma.^[11]

Clinical trials for diffuse large B-cell lymphoma are conducted at medical centers around the world, including locations in the United States, Europe, and other regions. Eligibility for specific trials depends on factors such as the stage of disease, previous treatments received, overall health status, and the specific characteristics of the lymphoma. Patients interested in clinical trials should discuss options with their healthcare team.

Most common treatment methods

• R-CHOP Chemoimmunotherapy
  • Combination of rituximab (a monoclonal antibody targeting CD20) with cyclophosphamide, doxorubicin, vincristine, and prednisone
  • Standard treatment regimen given in 21-day cycles, typically for six cycles
  • Can achieve cure in many patients with stage II disease
  • May be followed by radiation therapy in early-stage disease
• Modified Chemotherapy Regimens
  • R-EPOCH: Continuous infusion of etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin with rituximab over four days
  • R-CHOEP: Adds etoposide to standard R-CHOP combination
  • Pola-R-CHP: Combines polatuzumab vedotin-piiq with rituximab, cyclophosphamide, doxorubicin, and prednisone
  • Used in specific situations based on disease characteristics and patient factors
• Radiation Therapy
  • Often added after chemotherapy for stage II disease
  • Uses high-energy beams to destroy cancer cells in specific affected areas
  • Particularly useful for treating remaining disease in previously involved lymph node regions
  • Helps improve cure rates in limited-stage disease
• Targeted Therapies in Clinical Trials
  • Ibrutinib for ABC subtype of diffuse large B-cell lymphoma
  • Blocks specific enzymes involved in cancer cell growth and survival
  • Shown to be more effective in certain genetic subtypes of the disease
  • Being studied in Phase III trials combined with standard chemotherapy
• Advanced Options for Relapsed Disease
  • CAR T-cell therapy: Genetically modified immune cells designed to attack lymphoma cells
  • High-dose chemotherapy with autologous stem cell transplantation
  • Used when initial treatment fails or disease returns
  • Can provide significant benefit in selected patients